Cargando…

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program

BACKGROUND: Patients with type 2 diabetes (T2D) are predisposed to derangements in serum Magnesium (Mg), which may have implications for cardiometabolic events and outcomes. In clinical trials, participants with T2D randomized to sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have shown mild to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Katherine M., Li, JingWei, Bhalla, Vivek, Jardine, Meg J., Neal, Bruce, de Zeeuw, Dick, Fulcher, Greg, Perkovic, Vlado, Mahaffey, Kenneth W., Chang, Tara I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279612/ https://www.ncbi.nlm.nih.gov/pubmed/34277971 http://dx.doi.org/10.1002/edm2.247

Ejemplares similares

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
por: Zhou, Zien, et al.
Publicado: (2019)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
por: Neuen, Brendon L., et al.
Publicado: (2018)

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2019)

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
por: Rådholm, Karin, et al.
Publicado: (2018)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial
por: Neal, Bruce, et al.
Publicado: (2017)

Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results From the Randomized CANVAS Program Trials
por: Zhou, Zien, et al.
Publicado: (2019)

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
por: Ohkuma, Toshiaki, et al.
Publicado: (2020)

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA(1c), disease duration and treatment intensity: results from the CANVAS Program
por: Young, Tamara K., et al.
Publicado: (2021)

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials
por: Neal, Bruce, et al.
Publicado: (2017)

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2020)

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program
por: Yu, Jie, et al.
Publicado: (2021)

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
por: Fletcher, Robert A., et al.
Publicado: (2023)

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
por: Sen, Taha, et al.
Publicado: (2021)

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2021)

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
por: Fulcher, Greg, et al.
Publicado: (2015)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
por: Neuen, Brendon L., et al.
Publicado: (2020)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
por: Li, Jing‐Wei, et al.
Publicado: (2022)

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial
por: Mahaffey, Kenneth W., et al.
Publicado: (2019)

Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial
por: Rasmussen, Daniel Guldager Kring, et al.
Publicado: (2022)

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
por: Koshino, Akihiko, et al.
Publicado: (2022)

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis
por: Zhou, Zien, et al.
Publicado: (2021)

The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
por: Carbone, Salvatore, et al.
Publicado: (2019)

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials
por: Heerspink, Hiddo J Lambers, et al.
Publicado: (2009)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
por: Arnott, Clare, et al.
Publicado: (2020)

PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
por: Peters, Kirsten E., et al.
Publicado: (2020)

Effects of the Mediterranean Diet on Cardiovascular Outcomes—A Systematic Review and Meta-Analysis
por: Liyanage, Thaminda, et al.
Publicado: (2016)

Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
por: Neuen, Brendon L, et al.
Publicado: (2020)

Canagliflozin review – safety and efficacy profile in patients with T2DM
por: Jakher, Haroon, et al.
Publicado: (2019)

Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS
por: Borisov, Angel N, et al.
Publicado: (2023)

Canva
por: Gehred, Alison Paige
Publicado: (2020)

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
por: Wada, Takashi, et al.
Publicado: (2021)

Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE
por: Ferrannini, Giulia, et al.
Publicado: (2023)

HTML5 canvas
por: Fulton, Steve, et al.
Publicado: (2013)

HTML5 Canvas
por: Fulton, Steve, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_e51odg5q24u8lkbvbds2os82gn